Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
https://doi.org/10.22416/1382-4376-2019-29-1-17-23
Abstract
Aim: to analyze the data that has so far been accumulated on the pathogenetic association of gallstone disease (GD) and non-alcoholic fatty liver disease (NAFLD), as well as to assess the effect of cholecystectomy on the NAFLD course.
Key findings. The relationship between GD and NAFLD is very complex and seems to be mutually aggravating. There is no doubt that there is an increased risk of GB in NAFLD patients, which is primarily associated with common pathogenetic mechanisms. These include central and peripheral insulin resistance, changes in the expression of transcription factors (liver X-receptor and farnesoid X-receptor) and the bile acid membrane receptors (TGR5). Conversely, the effect of GD on the NAFLD course is assumed, although the pathogenetic factors of this association are still unknown. In recent years, convincing data has emerged concerning the role of cholecystectomy in the NAFLD progression, which may be connected with the development of small intestinal bacterial overgrowth, as well as with the disruption of the endocrine balance and the signal function of bile acids.
Conclusion. The connection between NAFLD, GD and cholecystectomy is complex and multifaceted. The study of this connection will allow new methods of treatment to be developed.
About the Author
Aleksey O. Bueverov
I.M. Sechenov First Moscow State Medical University (Sechenov University); M.F. Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI)
Russian Federation
Russian Federation
Dr. Sci. (Med.), Prof., Department of Medical and Social Expertise, Emergency and Outpatient therapy, Institute of Vocational Education; Leading researcher (MONIKI)
117556, Moscow, Fruktovaya str., 12
References
1. Sayiner M., Koenig A., Henry L., Younossi Z.M. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016;20:205–14.
2. Bellentani S. The epidemiology of nonalcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):81–4.
3. Brunt E.M., Wong V.W., Nobili V. et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080.
4. Estes C., Anstee Q.M., Arias-Loste M.T. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32121–4.
5. Adams L.A., Anstee Q.M., Tilg H., Targher G. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138–53.
6. Lammert F., Gurusamy K., Ko C.W. et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024.
7. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65:146–81.
8. Ruhl C.E., Everhart J.E. Gallstone disease is associated with increased mortality in the United States. Gastroenterology. 2011;140:508–16.
9. Mendez-Sanchez N., Bahena-Aponte J., Chavez-Tapia N.C. et al. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol. 2005;100:827–30.
10. Ahmed M.H., Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand J Gastroenterol. 2014;49:521–7.
11. Arrese M., Cortés V., Barrera F., Nervi F. Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship. Curr Opin Gastroenterol. 2018;34(2):90–6.
12. Chiang J.Y. Bile acid metabolism and signaling. Comprehens Physiol. 2013;3:1191–212.
13. Jaruvongvanich V., Sanguankeo A., Upala S. Significant association between gallstone disease and nonalcoholic fatty liver disease: a systematic review andmeta-analysis. Dig Dis Sci. 2016;61:2389–96.
14. Housset C., Chretien Y., Debray D., Chignard N. Functions of the gallbladder. Comprehens Physiol. 2016;6:1549–77.
15. Koller T., Kollerova J., Hlavaty T. et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012;47:197–203.
16. Loria P., Lonardo A., Lombardini S. et al. Gallstone disease in nonalcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005;20:1176–84.
17. Liu J., Lin H., Zhang C. et al. Nonalcoholic fatty liver disease associated with gallstones in females rather than males: a longitudinal cohort study in Chinese urban population. BMC Gastroenterol. 2014;14:213.
18. Chen L.Y., Qiao Q.H., Zhang S.C. et al. Metabolic syndrome and gallstone disease. World J Gastroenterol. 2012;18:4215–20.
19. Lin I.C., Yang Y.W., Wu M.F. et al. The association of metabolic syndrome and its factors with gallstone disease. BMC Fam Pract. 2014;15:138.
20. Fracanzani A.L., Valenti L., Russello M. et al. Gallstone disease is associated with more severe liver damage in patients with nonalcoholic fatty liver disease. PloS one. 2012;7:e41183.
21. Yilmaz Y., Ayyildiz T., Akin H. et al. Gallstone disease does not predict liverhistology in nonalcoholic fatty liver disease. Gut Liver. 2014;8:313–7.
22. Yki-Jarvinen H. Nonalcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901–10.
23. Yener O., Aksoy F., Demir M. et al. Gallstones associated with nonalcoholic steatohepatitis (NASH) and metabolic syndrome. Turk J Gastroenterol 2010;21:411–5.
24. Ruhl C.E., Everhart J.E. Relationship of nonalcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol. 2013;108:952–8.
25. Ioannou G.N. Cholelithiasis, cholecystectomy, and liver disease. Am J Gastroenterol. 2010;105:1364–73.
26. Kwak M.S., Kim D., Chung G.E. et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015;21:6287–95.
27. Yun S., Choi D., Lee K.G. et al. Cholecystectomy causes ultrasound evidence of increased hepatic steatosis. World J Surg. 2016;40:1412–21.
28. Nervi F., Arrese M. Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences? Am J Gastroenterol. 2013;108:959–61.
29. Shen C., Wu X., Xu C. et al. Association of cholecystectomy with metabolic syndrome in a Chinese population. PloS one. 2014;9:e88189.
30. Cortes V., Quezada N., Uribe S. et al. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in nonobese Hispanic patients: a pilot study. Lipids in health and disease. 2017;16:129.
31. Khaw K.B.C., Choi R.H., Kam J.H., Chakraborty B., Chow P.K.H. Interval increase in the prevalence of symptomatic cholelithiasis-associated non-alcoholic fatty liver disease over a ten-year period in an Asian population. Singapore Med J. 2017;58(12):703–7.
32. Lebedeva O.V., Bueverov A.O., Bueverova E.L., Nikitina L.O. The influence of cholecystectomy at a young age on the course of the metabolic syndrome in women. Almanac of Clinical Medicine. 2017;45(6):326–33 (In Rus.)
33. Zhu Q., Sun X., Ji X. et al. The association between gallstones and metabolic syndrome in urban Han Chinese: a longitudinal cohort study. Scientific Reports. 2016;6:29937.
34. Cortes V., Amigo L., Zanlungo S. et al. Metabolic effects of cholecystectomy: gallbladder ablation increases basal metabolic rate through G-protein coupled bile acid receptor Gpbar1-dependent mechanisms in mice. PLoS One. 2015;10:e0118478.
35. Biddinger S.B., Haas J.T., Yu B.B. et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008;14:778–82.
36. Rosso C., Mezzabotta L., Gaggini M. et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology. 2016;63:107–16.
37. Li S., Brown M.S., Goldstein J.L. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA. 2010;107:3441–6.
38. Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726–35.
39. Tanaka N., Aoyama T., Kimura S., Gonzalez F.J. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017;179:142–57.
40. Uppal H., Zhai Y., Gangopadhyay A. et al. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology. 2008;47:1331–42.
41. Jiang Z.Y., Parini P., Eggertsen G. et al. Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients. J Lipid Res. 2008;49:464–72.
42. Arab J.P., Karpen S.J., Dawson P.A. et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65:350–62.
43. Yu D.D., Andrali S.S., Li H. et al. Novel FXR (farnesoid X receptor) modulators: potential therapies for cholesterol gallstone disease. Bioorg Med Chem. 2016;24:3986–93.
44. Amigo L., Husche C., Zanlungo S. et al. Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice. Liver Int. 2011;31:52–64.
45. Portincasa P., Di Ciaula A., Wang H.H. et al. Coordinate regulation of gallbladder motor function in the gutliver axis. Hepatology. 2008;47:2112–26.
46. Roda E., Aldini R., Mazzella G. et al. Enterohepatic circulation of bile acids after cholecystectomy. Gut. 1978;19:640–9.
47. Deutschmann K., Reich M., Klindt C. et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim Biophys Acta. 2017. [Epub ahead of print]
48. Inagaki T., Choi M., Moschetta A. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217–25.
49. Kliewer S.A., Mangelsdorf D.J. Bile acids as hormones: the FXR-FGF15/19 pathway. Dig Dis. 2015;33:327–31.
50. Barrera F., Azocar L., Molina H. et al. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. Ann Hepatol. 2015;14:710–21.
51. Wojcik M., Janus D., Dolezal-Oltarzewska K. et al. A decrease in fasting FGF19 levels is associated with the development of nonalcoholic fatty liver disease in obese adolescents. J Pediat Endocrinol Metab. 2012;25(11– 12):1089–93.
52. Pols T.W., Noriega L.G., Nomura M. et al. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis. 2011;29:37–44.
53. Keitel V., Haussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol. 2012;36:412–9.
54. Thomas C., Gioiello A., Noriega L. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167–77.
55. Jones S.A. Physiology of FGF15/19. Adv Exp Med Biol. 2012;728:171–82.
56. Matsubara T., Li F., Gonzalez F.J. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368(1– 2):17–29.
Review
For citations:
Bueverov A.O. Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):17-23. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-1-17-23
Views:
1919
Email this article 
